https://www.cytodyn.com/newsroom/detail/666/c...a-study-in
Quote:
“While CytoDyn remains focused on developing leronlimab in oncology, and we are especially encouraged by the early readouts from our CLOVER Phase 2 study in patients with mCRC, the collaboration with Weill Cornell Medicine in the SALIENT-AD study represents an opportunity to explore potential patient benefit in an indication that represents a significant unmet need,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn.
Since this is a recent corporate publication can the encouraging statement on the CLOVER trial be considered a limited, but accurate, current update on the status of the data on the CLOVER trial? Asking for a third cousin.
Quote:
“While CytoDyn remains focused on developing leronlimab in oncology, and we are especially encouraged by the early readouts from our CLOVER Phase 2 study in patients with mCRC, the collaboration with Weill Cornell Medicine in the SALIENT-AD study represents an opportunity to explore potential patient benefit in an indication that represents a significant unmet need,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn.
Since this is a recent corporate publication can the encouraging statement on the CLOVER trial be considered a limited, but accurate, current update on the status of the data on the CLOVER trial? Asking for a third cousin.
5
